Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-09-16

Last Posted Date: 2013-05-30

Lead Sponsor: Loyola University

Registration Number: NCT00004905

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma

Phase 1

Completed

Conditions: Brain Tumors
Central Nervous System Tumors

Interventions: Drug: cyclosporine
Drug: etoposide
Drug: vincristine sulfate
Radiation: radiation therapy

First Posted Date: 2004-09-13

Last Posted Date: 2014-07-28

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 7

Registration Number: NCT00003625

Locations: 🇺🇸
Baptist Hospital of Miami, Miami, Florida, United States
🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Lucile Packard Children's Hospital at Stanford, Palo Alto, California, United States

and more 71 locations

Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Leukemia

Interventions: Biological: filgrastim
Drug: cladribine
Drug: cytarabine
Drug: etoposide
Drug: methotrexate
Drug: mitoxantrone hydrochloride
Drug: therapeutic hydrocortisone
Procedure: allogeneic bone marrow transplantation
Procedure: autologous bone marrow transplantation
Procedure: peripheral blood stem cell transplantation
Radiation: low-LET cobalt-60 gamma ray therapy
Radiation: low-LET electron therapy
Radiation: low-LET photon therapy

First Posted Date: 2004-09-02

Last Posted Date: 2014-07-24

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 115

Registration Number: NCT00002805

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

and more 35 locations

High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2004-08-31

Last Posted Date: 2010-10-01

Lead Sponsor: Temple University

Registration Number: NCT00002509

Locations: 🇺🇸
Temple University Cancer Center, Philadelphia, Pennsylvania, United States

Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors

Phase 2

Completed

Conditions: Extragonadal Germ Cell Tumor
Ovarian Cancer

First Posted Date: 2004-08-30

Last Posted Date: 2013-06-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00002489

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2004-08-30

Last Posted Date: 2013-06-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00002471

Locations: 🇺🇸
Kaplan Cancer Center, New York, New York, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 1 locations

Combination Chemotherapy in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Who Have Not Responded to Anthracycline-Containing Combination Chemotherapy

Phase 2

Conditions: Lymphoma

First Posted Date: 2004-08-30

Last Posted Date: 2013-09-17

Lead Sponsor: Ottawa Regional Cancer Centre

Registration Number: NCT00002488

Locations: 🇨🇦
Ottawa Regional Cancer Center - General Division, Ottawa, Ontario, Canada
🇨🇦
Ottawa Regional Cancer Centre - Civic Campus, Ottawa, Ontario, Canada

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-08-23

Last Posted Date: 2013-05-30

Lead Sponsor: Hackensack Meridian Health

Registration Number: NCT00004906

Locations: 🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

and more 1 locations